Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Candida auris has simultaneously emerged on five continents as a fungal pathogen causing nosocomial outbreaks. The challenges in the treatment of C. auris infections are the variable antifungal susceptibility profiles among clinical isolates and the development of resistance to single or multiple classes of available antifungal drugs. Here, the in vitro susceptibility to echinocandin antifungal drugs was determined and FKS1 sequencing was performed on 106 C. auris clinical isolates. Four isolates were identified to be resistant to all tested echinocandins (MIC ≥ 4 mg/liter) and harbored an S639F mutation in FKS1 hot spot region 1. All remaining isolates were FKS1 wild type (WT) and echinocandin susceptible, with micafungin being the most potent echinocandin (MIC 50 = 0.125 mg/liter). Antifungal susceptibility testing with caspofungin was challenging due to the fact that all FKS1 WT isolates exhibited an Eagle effect (also known as the paradoxical growth effect), which occurred at various intensities. To assess whether the Eagle effect resulted in pharmacodynamic resistance, 8 representative isolates were evaluated for their in vivo drug response in a murine model of invasive candidiasis. All isolates were susceptible to caspofungin at a human therapeutic dose, except for those harboring the S639F mutation. The data suggest that only isolates carrying mutations in FKS1 are echinocandin resistant and that routine in vitro testing of C. auris isolates for susceptibility to caspofungin by the broth microdilution method should be viewed cautiously or avoided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, isochromosome (5L), a specific aneuploidy in C. albicans, results in the formation of two extra copies of the left arm of chromosome 543, and, consequently, extra copies of TAC1 and ERG11, genes that confer resistance to azoles in these strains50.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [43]
In the citing paper
“Copy number variations, including whole-chromosome aneuploidy and shorter-range amplifications, are genome changes that can increase resistance32,43–49.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [43]
In the citing paper
“Importantly, limited ECN susceptibility was reported for all 3 isolates in a previous study (36), thus confirming the robustness of our phenotyping.”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [36]
In the citing paper
“Based on CDC-suggested breakpoints for ECNs (MICs of >4 μg/mL for AFG and MFG and >2 μg/mL for CSP [37]), these isolates can be considered ECN-R, as pointed out previously (36).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [36]
In the citing paper
“The clinical features of these infections include biofilm persistence on abiotic surfaces and skin, immune evasion, and antifungal drug resistance (7–12).”
From Dual function of Candida auris mannosyltransferase, MNT5, in biofilm community protection from antifungal therapy and the host (2025) · cites this paper as [9]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
How to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881 · cited 1×
“The sample size of this animal experiment was considered adequate on the basis of the resource equation method (49).”
MethodLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 5×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundInfluentialSelf-citationSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
First hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768
Self-citationChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
Self-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 2×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 12×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundResultInfluentialSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
Calvo, B., Melo, A. S. A., Perozo-Mena, A., Hernandez, M., Francisco, E. C., Hagen, F., Meis, J. F., & Colombo, A. L. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.07.008 · Cited by 448
Research works printed but not linked: 2
- Public Health England. 2017. Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris. Last updated 11 August 2017. Public Health England, London, United Kingdom.
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Items 201–259 of 259
Gifford, H., Pradhan, A., Caswall, B. A., Murphy, S. E., Leaves, I., Edmondson, M. B., Chakraborty, T., Wilson, D., Taori, S. K., Gow, N. A. R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76954-x · Cited by 3
“Typical resistance is thought to arise primarily through mutations in FKS1 hot-spots 29 – 34 that lead to treatment failure in vivo, as demonstrated in murinecandidiasismodels 35,36 .”
Candida auris: Steckbrief eines neuen Pilzes
Wagener, J., & Kurzai, O. (2019) · Deutsches Ärzteblatt · doi:10.3238/persinfek.2019.07.22.01 · Cited by 3
COVID-19 pandemic and the evolving epidemiology of Candidemia: A topic of concern!!!
Rajni, E., Garg, V. K., Vohra, R., Jangid, Y., & Sharma, R. (2022) · Novel Research in Microbiology Journal · doi:10.21608/nrmj.2022.259623 · Cited by 2
Multi-resistant Candida Species: A Global Public Health Problem: A Systematic Review
Vital, E. L., & Carnovale, S. I. (2023) · SCT Proceedings in Interdisciplinary Insights and Innovations. · doi:10.56294/piii2023162 · Cited by 2
Tracking the origin and evolution of multidrug resistance in Candida auris
Papon, N., & Sanglard, D. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30124-5 · Cited by 2
Ramos, L. S., Silva, L. N., de Mello, T. P., Frota, H. F., Branquinha, M. H., & dos Santos, A. L. S. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220520153748 · Cited by 3
Reichert, T. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2019.tde-27062019-103116 · Cited by 3
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Self-citationCytochrome bc1 Catalytic Subunit Rip1 Modulates Antifungal Tolerance in Candida auris
Phan-Canh, T., Lackner, M., Chauhan, M., Zenz, L.-M., Chauhan, N., & Kuchler, K. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c01058 · Cited by 1
Candida (Candidozyma) Auris: From Colonization to Invasive Disease
ARIKAN, H. B. A., & Sezak, N. (2025) · Forbes Journal of Medicine · doi:10.4274/forbes.galenos.2025.00378 · Cited by 1
Chimeric Antigen Receptor (CAR)-based and Other Novel Immunotherapies for Invasive Candidiasis
Guimarães, J. G., Carvalho, S. L., Marangoni, M. E. D., Lee, C., da Silva, T. A., & de Campos, G. Y. (2025) · Infectious diseases · doi:10.5772/intechopen.1013127 · Cited by 1
A study of resistome of Candidozyma auris from 20 year genomic datasets
Elantamilan, D., Rajbongshi, J., & Mangayarkarasi, V. (2026) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2026.101111 · Cited by 1
Negi, P., Verma, N., Rishi, P., Multani, K., Sharma, M., Kumari, S., & Raj, K. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04864-z · Cited by 1
“Despite this, a link between echinocandin susceptibility and FKS1 gene polymorphisms has been discovered, (Biswal et al. 2017; Kordalewska et al. 2018) suggesting that antifungal resistance has evolved and may also be clinically significant in this context.”
Du, X., & Li, L. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1873741 · Cited by 1
“Such resistance is primarily mediated by FKS1 hotspot mutations (detailed in Section 5.4), resulting in cross-resistance to all echinocandin agents (Kordalewska et al., 2018; Sharma et al., 2022).”
InfluentialCandida species: the silent enemy
Al-laaeiby, A. I. E., Ali, S. M., & Al-Saadoon, A. H. (2019) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v20i4.1 · Cited by 3
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Self-citationCandida auris can acquire antifungal resistance without selection pressurePreprint
Phan-Canh, T., Nguyen-Le, D.-M., Chauhan, M., Luu, P., Chowdhary, A., Chauhan, N., & Kuchler, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.07.695227 · Cited by 3
“Echinocandin resistance is predominantly associated with hotspot-1 substitutions in FKS1 (S639F/P/Y) [2,18–20], while the role of C. auris FKS2 remains unclear.”
Self-citationSchwartz, I. S., Smith, S., & Dingle, T. (2018) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v44i11a01f · Cited by 1
“La résistance aux échinocandines est présente dans près de 2 à 5 % des isolats (5,28,29).”
Candida auris: A New, Threatening Yeast
Pemán, J., & Gaitán, A. C. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21000-5
Lepak, A. J., & Andes, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.00018-4 · Cited by 2
Trentin, G. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2022.tde-20062022-161952
Barreto, T. L. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2020.tde-13012022-165803
Candida Auris : What do We Know about the Most Enigmatic Pathogen of the 21 st Century?
Bogut, A. (2023) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.2478/am-2023-0003
Candida auris as a significant emerging human fungal pathogen
Pruc, M., Krajsman, M. J., Feduniw, S., Szczepanski, P., Holzer, J., Jaroszewska, A., & Szarpak, Ł. (2023) · Disaster and Emergency Medicine Journal · doi:10.5603/demj.a2023.0014
Retraction: Candida auris: Virulence and antifungal drugs resistance
Al-Garawi, N. A.-H. D., Meri, M. A., & Sahib, R. A. (2023) · AIP conference proceedings · doi:10.1063/5.0181986
RetractedEmerging Saccharomycotina yeast pathogens: Detection and susceptibility profiles
Stavrou, A. A. (2021) · UvA-DARE (University of Amsterdam) · doi:10.5281/zenodo.5558633
Erganiş, S., Şahin, E. A., Öztürk, A., Yıldız, P. A., Şahin, C., Top, Ö. Ö., & Tunçcan, Ö. G. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3202
Technologies of medical diagnosis and treatment of invasive candidiasis in children
Mokia-Serbina, S. O., Sheiko, S. O., Фесенко, В. І., Lytvynova, T. М., Zabolotnia, N. I., & Shelevytska, V. (2025) · CHILD`S HEALTH · doi:10.22141/2224-0551.20.1.2025.1796
How do ‘Candida auris’ and other fungi develop drug resistance? A microbiologist explains
Gardner, J. (2023) · The Conversation · doi:10.64628/aai.vyvq349ce
MOLECULAR DETERMINANTS OF ANTIFUNGAL RESISTANCE IN CANDIDA AURIS
Bazarova, G. (2024) · Natural Sciences in the Modern World · doi:10.70413/zdtf-v03-i12-s19983
Κουτσοδήμου, Ι. Μ. (2024) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.41506
Wang, Y. (2023) · MacSphere (McMaster University) · doi:10.71548/17335 · Cited by 1
Gaitán, A. C. R. (2020) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
Özmerdiven, G. E., & İrvem, A. (2026) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2026.101065
First report of Candidozyma auris in Vietnam
Phú, T. T., Nguyen, A. T., & Nguyễn, S. T. (2026) · BMC Microbiology · doi:10.1186/s12866-025-04583-3
“Here, the paradoxical effect explanation becomes relevant, since high in vitro concentrations have not been shown to correlate with in vivo concentrations with isolates not carrying the FKS1 mutation [21].”
Rapid quantification of both fungal abundance and drug resistance via reaction kinetics
Zhang, Y., Li, C., & Deng, R. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01619-5
Methods for skin load reduction of Candida auris: a systematic review
Du, Y., Lu, Y., Qiao, F., Jin, H., Lin, S., Wang, Z., Mandizadza, O. O., Ji, C., & Gan, T. (2026) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-026-01719-6 · Cited by 1
Purusothman, P., Menzo, S. L., Scaglione, V., Sasset, L., Franchin, E., Vecchio, C. D., Cillo, U., Tiberio, I., Baldo, V., Caielli, P., et al. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108511
L'interaction Hsp90/co-chaperonnes : nouvelle cible pour le traitement des candidoses invasives
Rouges, C. (2023) · theses.fr (ABES) · doi:10.70675/40b24a3fz159ez4d8ez8a34zdd8ffa1c22fa
Harnessing random peptide mixtures to combat multidrug-resistant fungal infections
Adeoye, J. A., Belo, Y., Rocha, M. C., Hayby, H., Israyilova, A., Hayouka, Z., & Shlezinger, N. (2026) · mBio · doi:10.1128/mbio.00400-26
“Echinocandins, despite favorable safety profiles, are susceptible to resistance in C. auris , while amphotericin B and azoles are constrained by toxicity and drug-drug interactions, respectively (68, 69).”
The Epidemiology and Infection Control of Candida Auris in Shanghai
Wei, M., Guo, J., Li, L., ZHU, J., Xue, Y., Chen, G., Yang, F., Wu, W., & Zhu, M. (2026) · Mycoses · doi:10.1111/myc.70176
Bohner, F., Szilovics, Z., Veres, É., Papp, C., Nosanchuk, J. D., & Gácser, A. (2026) · Virulence · doi:10.1080/21505594.2026.2664993
“According to widespread anti-fungal susceptibility data, micafungin is considered one of the most potent therapeutic and prophylactic agents against C. auris [14,15].”
Siopi, M., Leventaki, S., Pachoulis, I., Rentoumi, A., Argyris, N., Spruijtenburg, B., Meijer, E. F. J., Meis, J. F. G. M., Pournaras, S., Tsakris, A., et al. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.00130-26 · Cited by 1
“In fact, FKS1 WT strains can display variable inhibition patterns in the presence of increasing caspofungin concentrations, yet paradoxical growth does not translate into poor in vivo response (34).”
Antifungal peptides for biofilm disruption: Mechanisms, design strategies, and translational outlook
Saini, Y., Wani, M. Y., & Hameed, S. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108601 · Cited by 1
Hameed, T., John, L. L. H., Bignell, E., & Tanaka, R. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.19.733372
“Combinations with AFG were prioritised because AFG is an echinocandin, which is the current recommended first line antifungal drug [12,13], almost always used in monotherapy and against which resistance is steadily emerging [14].”
Antifungal resistance: from classical mechanisms to the expanding role of acetyltransferases
Werneck, S. M. C., Gouveia‐Eufrásio, L., de Freitas, G. J. C., de Carvalho, D. S., César, I. C., Rossato, L. L., Bastos, R. W., Peres, N. T. A., & Santos, D. A. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01273-8
“Classical antifungal resistance mechanisms include alterations in drug targets, gene amplification events, transcriptional regulation of sterol biosynthesis and efflux pumps, as well as activation of stress-response pathways [10–13].”
Osama, D., Alsedawy, M., Hussein, M. S., Hassan, M. A., Elrefaey, S. M., & Tawfick, M. M. (2026) · Antonie van Leeuwenhoek · doi:10.1007/s10482-026-02393-9
“However, studies suggest that mutations in genes involved in ergosterol biosynthesis contribute to amphotericin B resistance, including the ERG2 , ERG3 and ERG6 genes (Kordalewska et al. 2018; Bhattacharya et al. 2019; Frías-De-León et al. 2020).”
Du, X., Meng, Q., Wang, L., & Zhang, Z. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s619168
Spruijtenburg, B., Ünal, N., do Prado, C. M., Meis, J. F. G. M., Bingöl, O., Toyran, T., Akar, N., Ay, N., Gülen, T. A., Turunç, T., et al. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.109045
Phan-Canh, T., Elbe‐Bürger, A., & Kuchler, K. (2026) · Trends in Microbiology · doi:10.1016/j.tim.2026.08.011
Non-albicans Candida Species: Epidemiology and Antifungal Resistance
Bosan, M. A., Durrani, A. D., Faiz, A., Farooqi, J. Q., & Jabeen, K. (2026) · Current Fungal Infection Reports · doi:10.1007/s12281-026-00542-1
Satia, S., Pfeiffer, J., Kılıç, A., Furuya, E. Y., Smithgall, M. C., MANSUKHANI, M. M., Hsiao, S., Shi, J., Kumar, R., Green, D. A., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01695-26
“In this study, WGS provides additional support that resistance to fluconazole was linked to mutations in the ERG11 , CDR1, and TAC1B genes, consistent with earlier reports (22, 23).”
Kamasah, J. S., Akin, B. E., Baker, L. J., Taba, A., Mahjouri‐Samani, M., & Hasim, S. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00184-26
“First, the C. auris strains used in the present study differ from those examined by Horton et al., and strain-to-strain variability in echinocandin responsiveness has been previously described in C. auris (36, 37).”
Kainthola, K. (2025) · Journal of chemical health risks
Andreev, S. S., Yatskov, K. V., Ryazantseva, E. V., Isaev, T. K., Николаевич, Т. Р., Kuznetsova, D. S., Желнова, Е. И., & Анатольевна, Л. М. (2026) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2026.2.344-352
Siopi, M., Leventaki, S., Pachoulis, I., Spruijtenburg, B., Meijer, E. F. J., Meis, J. F. G. M., Pournaras, S., Tsakris, A., Vrioni, G., & Meletiadis, J. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag361
Reich, M., Czajka, K. M., Hourtovenko, C., Kinkar, E., Saleh, M. T., Michael, P., Saunders, D., Appanna, V. D., & Tharmalingam, S. (2026) · Journal of Fungi · doi:10.3390/jof12110833
Metadata
- Authors
- Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S.
- Affiliations
- Rutgers Health (US)
- Medical and Experimental Mycology Group, Corporación para Investigaciones Biológicas (CIB), Medellín, Colombia
- University of Delhi (IN)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-06
- Volume
- 62
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5971591
- OpenAlex
- W2795884050
- Cited by
- 247
- References
- 47
- Citations by year
- 2026: 29 · 2025: 24 · 2024: 22 · 2023: 29 · 2022: 29 · 2021: 43 · 2020: 36 · 2019: 24 · 2018: 10
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (AI109025)
- Astellas Pharma US
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- Candida auris, echinocandin resistance, FKS1 mutations, caspofungin, micafungin, antifungal susceptibility testing, invasive candidiasis, mouse model, nosocomial fungal infections
- MeSH terms
- Animals, Antifungal Agents, Candida, Candidiasis, Cross Infection, Female, Glucosyltransferases, Humans, Mice, Inbred BALB C, Microbial Sensitivity Tests, Drug Resistance, Fungal, Mice, Echinocandins, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.